Drug information for RAPTIVA
Form
Dosage
Status
Therapeutic Equivalence
Active Ingred
Ref.
Sponsor
Document
VIAL; SUBCUTANEOUS
125MG/VIAL
Discontinued
EFALIZUMAB
efalizumab
GENENTECH
125075
2012-04-18 Other Important Information from FDA
2009-11-20 Medication Guide
2009-03-16 Letter
2009-03-16 Label
2008-10-23 Letter
2008-10-23 Letter
2005-06-16 Letter
2005-06-16 Label
2004-10-25 Review
2003-11-18 Letter
Drug Adverse Effects information for RAPTIVA
Role code
Indications
Reaction
# Reports
SS
BLOOD PRESSURE
LYMPHADENOPATHY
1
SS
BLOOD PRESSURE
SQUAMOUS CELL CARCINOMA
1
SS
PSORIASIS
LYMPHADENOPATHY
2
SS
PSORIASIS
LYMPHOCYTOSIS
2
SS
PSORIASIS
MANTLE CELL LYMPHOMA
2
SS
PSORIASIS
SQUAMOUS CELL CARCINOMA
2
C
PRODUCT USED FOR UNKNOWN INDICATION
DRUG INEFFECTIVE
1
C
PRODUCT USED FOR UNKNOWN INDICATION
GAIT DISTURBANCE
1
C
PRODUCT USED FOR UNKNOWN INDICATION
INJECTION SITE PAIN
1
C
PRODUCT USED FOR UNKNOWN INDICATION
LYMPHOMA
1
C
PRODUCT USED FOR UNKNOWN INDICATION
METASTATIC RENAL CELL CARCINOMA
3
C
PRODUCT USED FOR UNKNOWN INDICATION
PAIN IN EXTREMITY
1
C
PRODUCT USED FOR UNKNOWN INDICATION
PSORIASIS
1
C
PRODUCT USED FOR UNKNOWN INDICATION
SCAR
1
C
PRODUCT USED FOR UNKNOWN INDICATION
SKIN FISSURES
1
C
PRODUCT USED FOR UNKNOWN INDICATION
STAPHYLOCOCCAL INFECTION
1
C
PSORIASIS
METASTATIC RENAL CELL CARCINOMA
1
C
PSORIASIS
PROSTATE CANCER
1
C
PSORIASIS
PSORIASIS
1
Ads by Google